Kidney Cancer Journal Volume 16, Number 2
Few topics have generated as much controversy and debate as determining the optimal approach for cyto-reductive nephrectomy in the targeted therapy era. Although the paradigm has been
In this wide ranging interview, Nicholas J. Vogelzang, MD, FASCO, FACP, shares insights, perspectives, and real-world observations from his practice following the
Kidney Cancer Journal Volume 16, Number 2
As the population of patients treated with immune checkpoint blockade expands and with even more agents likely to be approved there is a growing need for
Kidney Cancer Journal Volume 16, Number 2
The Food and Drug Administration has granted approvals to nivolumab and ipilimumab (Opdivo and Yervoy) in combination for the treatment of intermediate or
Kidney Cancer Journal Volume 16, Number 2
Patients with RCC and physicians who treat RCC completed an online discrete-choice experiment survey. In a series of 12 questions, respondents chose between
Kidney Cancer Journal Volume 16, Number 2
Kidney Cancer Journal Volume 16, Number 2
Kidney Cancer Journal Volume 16, Number 1
In the past decade, the treatment of renal cell carcinoma (RCC) has advanced more rapidly than at any other time in medical history. Better imaging techniques have led to
Kidney Cancer Journal Volume 16, Number 1
Renal cell carcinoma (RCC) is the 8th most common cancer in the United States with an estimated incidence of 63,990 causing 14,400 deaths in 2017 according to
The trajectory of recent work on the pathophysiology of renal cell carcinoma (RCC) suggests the extent to which a spectrum of disorders share a common genetic
Kidney Cancer Journal Volume 16, Number 1
Axitinib with pembrolizumab has been shown to be tolerable and to exhibit promising antitumor activity in treatment-naïve patients with advanced renal cell carcinoma